Treeline Biosciences to go public via reverse merger with Standard BioTools, securing runway to 2029

Treeline Biosciences announced that it will become a publicly traded company through a reverse merger with Standard BioTools. The transaction is expected to list the combined entity on a U.S. exchange.

The deal is designed to provide Treeline with sufficient cash to fund its operations through 2029, extending its financial runway without a traditional IPO.

Both companies said the merger will allow Treeline to focus on its research and development pipeline while leveraging Standard BioTools' infrastructure and market presence.

Details on valuation, share distribution, or timing of the listing were not disclosed in the brief announcement.